SILVER SPRING, Md., Oct. 28 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its results of operations for the quarter ended September 30, 2010.
Total revenues for the third quarter of 2010 were $171.0 million, up from $97.2 million for the same quarter in 2009. Net income for the third quarter of 2010 was $39.7 million, or $0.70 per basic share, compared to net income of $11.9 million, or $0.22 per basic share, for the same quarter in 2009. Gross margin from sales was $148.9 million for the third quarter of 2010, compared to $84.2 million for the same quarter last year. Earnings before non-cash charges, a non-GAAP financial measure(1), was $99.1 million for the third quarter of 2010 compared to $40.6 million for the third quarter of 2009.
"We had a good quarter as the demand for our core products continues to grow," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "Having approvals for multiple products is making a positive difference in our growth rate and in the number of patients that we can help compared to last year."
(1) See definition of earnings before non-cash charges and a reconciliation of net income to earnings before non-cash charges below.
Financial Results for the Three Months Ended September 30, 2010RevenuesThe following table sets forth the components of net revenues (dollars in thousands):Three Months Ended
September 30,20102009Percentage Change Cardiopulmonary products:Remodulin$
87,40025.4%Tyvaso48,7175,113852.8%Adcirca9,9351,514556.2%Telemedicine services and products2,4082,904(17.1)%Other33928419.4%Total net revenues$
97,21575.9%The growth in revenues for the three months ended September 30, 2010 reflects the continued increase in the number of patients being prescri
|SOURCE United Therapeutics Corporation|
Copyright©2010 PR Newswire.
All rights reserved